Patients with hereditary angioedema who were treated with an antisense oligonucleotide treatment, donidalorsen, experienced significantly fewer attacks than patients who received placebo, a phase II trial showed. Over 17 weeks, the mean number of investigator-confirmed angioedema attacks was 0.23 per month among the 14 patients treated with donidalorsen 80 mg every 4 weeks compared with
Allergies & Asthma
The first generic version of Symbicort — a metered-dose inhaler that combines the corticosteroid budesonide with the long-acting bronchodilator formoterol — has been approved for asthma and chronic obstructive pulmonary disease (COPD), the FDA announced on Tuesday. In asthma, the combination is indicated for adults and kids ages 6 and older to prevent symptoms (not
If you’re ready for a cold and snowy winter season to end (we may be biased here in the Midwest!), there’s nothing quite like the thought of spring, budding trees, blooming flowers, the first robin sighting, and hope for warmer days ahead. But, with budding trees comes the start of “hay fever” season. Tree pollen
PHOENIX — Exacerbation-prone asthma patients who had high blood eosinophil counts or elevated fractional exhaled nitric oxide (FeNO) appeared to benefit from lebrikizumab, pooled data from two disappointing phase III trials suggested. In the post-hoc analysis of LAVOLTA I and LAVOLTA II, patients with at least one exacerbation in the prior year who had high
PHOENIX – Patients who have nasal polyps appeared to get symptom relief when treated with omalizumab (Xolair) regardless of comorbid asthma, according to a post-hoc trial analysis. All patients taking omalizumab achieved deep drops in symptoms on various tests and improvements remained even after the study drug was discontinued during a follow-up period compared with
PHOENIX — Patients with severe, uncontrolled asthma experienced greater relief throughout the year when treated with the biologic tezepelumab (Tezspire) versus placebo, according to findings from the phase III NAVIGATOR study. Over 52 weeks, tezepelumab significantly reduced the annualized asthma exacerbation rate by 56% in the overall study population (P<0.001), and by 41% in those
PHOENIX — Adding mepolizumab (Nucala) to guideline-based care reduced flare-ups in disadvantaged kids with exacerbation-prone, eosinophilic asthma, the yearlong MUPPITS-2 trial showed. In the randomized study of nearly 300 kids living in urban parts of the U.S., the annualized exacerbation rate was 0.96 with mepolizumab versus 1.30 with placebo, representing a 27% relative decrease (rate
Children who received mechanical ventilation at a pediatric intensive care unit (PICU) had slightly worse cognitive outcomes in the long run compared with their siblings, a prospective cohort study found. At 3 to 8 years after discharge from a PICU, kids who had received mechanical ventilation for acute respiratory failure had a mean estimated IQ
PHOENIX — Experts in lung diseases debated at the annual meeting of the American Academy of Allergy, Asthma & Immunology here whether at-home spirometry tests and devices, which are now available from multiple companies, should be elevated to prime-time use. The tests are good enough to allow patients to monitor their lung function at home
A drug-eluting contact lens containing an antihistamine for people with allergic eye itch won approval from the FDA, Johnson & Johnson Vision Care announced. The daily disposable etafilcon A drug-eluting contact lens with ketotifen (Acuvue Theravision with ketotifen) is the world’s first drug-eluting contact lens, the company said. It recently was approved in Japan and
PHOENIX — Treatment with the interleukin-5 (IL-5) antagonist mepolizumab (Nucala) reduced the need to take oral corticosteroids by 75% in patients who had depended on the steroids to control symptoms of severe asthma, a researcher reported here. Patients on a median 10 mg maintenance dose of oral corticosteroids at baseline reduced their intake to 2.5
PHOENIX — In some patients with eosinophilic asthma, dupilumab (Dupixent) offered the highest chance of better lung function, although the agent also carried the highest odds of serious adverse events (AEs), a researcher reported. In an indirect treatment comparison of dupilumab, mepolizumab (Nucala), and benralizumab (Fasenra), patients with eosinophil counts ≥300 cells/μL treated with dupilumab
Seasons change… Trees and flowers start budding to form colorful landscapes. Green-leafed trees change into a rainbow of fall colors. Those fall colors turn into a winter wonderland. Sounds pretty, right? What isn’t pretty — the misery that seasonal allergies often bring. Even though allergies cause problems year round, a number of environmental allergens “peak”
PHOENIX — Biologic medications sent severe asthma into remission in a substantial proportion of patients, according to a study presented here at the annual meeting of the American Academy of Allergy, Asthma & Immunology. About 35% of 908 patients who took biologic treatments for at least 12 months were able to achieve remission status, reported
PHOENIX — Nearly three-fifths of patients with eosinophilic esophagitis (EoE) achieved remission after treatment with dupilumab (Dupixent), researchers reported. In a 6-month study, 58.8% of adults and adolescents treated with dupilumab achieved histological remission compared to 6.3% in the placebo group (P<0.0001), according to Marc Rothenberg, MD, PhD, of Cincinnati Children’s Hospital, in a pre-recorded
Black and Latinx patients who used an inhaled glucocorticoid as needed along with usual care had improved asthma outcomes, according to results from the PREPARE trial. In the study of patients with moderate-to-severe asthma, and compared to a control group that continued usual care only, the intervention group experienced a 15% decrease in risk of
Obesity may put women at a higher risk for airway obstructive diseases, a Korean population-based cohort study suggested. In an adjusted model, premenopausal women with severe obesity had a 67% higher risk for chronic obstructive pulmonary disease (COPD; HR 1.67, 95% CI 1.54-1.81), while postmenopausal women had a 57% elevated risk (HR 1.57, 95% CI
Allergies are the 6th leading cause of chronic illness in the U.S. A majority of people avoid their allergens, manage their symptoms with temporary relief from over-the-counter (OTC) allergy medications, or just continue to suffer. Did you know there’s a personalized treatment to modify allergies and allergy-related chronic conditions beyond temporary relief? In this blog,
Patients who switched from a pressurized metered dose inhaler (pMDIs) to a dry powder inhaler (DPI) halved their carbon footprints while still maintaining good asthma control, a post-hoc analysis of the Salford Lung Study in Asthma showed. Including both maintenance and rescue asthma treatment, the annual per-patient carbon footprint equivalent (CO2e) dropped from a least
Traveling to your dream vacation destination or on a business trip should bring relaxation, good memories or productivity – not allergy flare ups. In a recent blog, we covered what to know about traveling with food allergies. Now, we’ll focus on traveling tips to stay safe from non-food allergens. Up to 40% of the population
TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center in El Paso, look at the top medical stories of the week. This week’s topics include treating young children for peanut allergy,
Workplace exposure to pesticides was linked to a higher risk of chronic obstructive pulmonary disease (COPD), a large U.K. study found. Risk of COPD increased among adults ages 40-74 ever exposed to pesticides on the job (prevalence ratio [PR] 1.13, 95% CI 1.01-1.28), reported Sara De Matteis, MD, PhD, MPH, of Imperial College London, and
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »